STAT Plus: Sanofi MS drug reduced brain lesions in preliminary study

An experimental multiple sclerosis pill the drug giant Sanofi has touted as one of its big research hopes reduced the number of lesions in a 130-patient study.

The drug, known as SAR442168, works by inhibiting a cellular signal called Bruton’s tyrosine kinase (BTK), which is also the target of the best-selling cancer drug Imbruvica. Unlike other BTK inhibitors, the Sanofi drug can get through the so-called blood-brain barrier into the brain, making it potentially useful in MS.

Continue to STAT Plus to read the full story…

Read Original Article: STAT Plus: Sanofi MS drug reduced brain lesions in preliminary study »